GlaxoSmithKline receives EU approval for Tafinlar
4 September 2013 11:04 in Pharmaceutical Company Product News
GlaxoSmithKline has announced that the European Commission has approved its innovative new melanoma therapy Tafinlar.
The oral targeted treatment is indicated for use as a monotherapy for unresectable melanoma or metastatic melanoma in adult patients with a BRAF V600 mutation, with patients needing to take a test to confirm the presence of this mutation before they begin treatment.
It represents a promising new therapy option for the most serious and deadly form of skin cancer, with evidence from clinical trials showing the significant survival benefits it can provide.
GlaxoSmithKline has been able to bring this product to market within five years of commencing initial testing.
Dr Paolo Paoletti, president of GlaxoSmithKline Oncology, said: "With this new personalised medicine, we hope to make a meaningful difference in the lives of appropriate patients with metastatic melanoma."
This comes after the European Commission approved GlaxoSmithKline's drug Tyverb in a new indication for breast cancer last month.
Other news stories from 04/09/2013
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Axonn News Agency